Edgewise Therapeutics Statistics
Total Valuation
EWTX has a market cap or net worth of $1.92 billion. The enterprise value is $1.45 billion.
Important Dates
The last earnings date was Monday, March 3, 2025, before market open.
| Earnings Date | Mar 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EWTX has 95.21 million shares outstanding. The number of shares has increased by 45.02% in one year.
| Current Share Class | 95.21M |
| Shares Outstanding | 95.21M |
| Shares Change (YoY) | +45.02% |
| Shares Change (QoQ) | +0.97% |
| Owned by Insiders (%) | 0.56% |
| Owned by Institutions (%) | 65.92% |
| Float | 54.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.16 |
| P/TBV Ratio | 4.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.93, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.93 |
| Quick Ratio | 19.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.40% and return on invested capital (ROIC) is -25.19%.
| Return on Equity (ROE) | -34.40% |
| Return on Assets (ROA) | -24.01% |
| Return on Invested Capital (ROIC) | -25.19% |
| Return on Capital Employed (ROCE) | -34.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.22M |
| Employee Count | 110 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.36% in the last 52 weeks. The beta is 0.23, so EWTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +10.36% |
| 50-Day Moving Average | 26.08 |
| 200-Day Moving Average | 25.48 |
| Relative Strength Index (RSI) | 28.86 |
| Average Volume (20 Days) | 1,562,927 |
Short Selling Information
The latest short interest is 9.09 million, so 9.55% of the outstanding shares have been sold short.
| Short Interest | 9.09M |
| Short Previous Month | 8.73M |
| Short % of Shares Out | 9.55% |
| Short % of Float | 16.70% |
| Short Ratio (days to cover) | 6.69 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -158.83M |
| Pretax Income | -115.88M |
| Net Income | -133.81M |
| EBITDA | -156.76M |
| EBIT | -158.83M |
| Earnings Per Share (EPS) | -$1.45 |
Full Income StatementBalance Sheet
The company has $470.17 million in cash and $4.74 million in debt, giving a net cash position of $465.43 million or $4.89 per share.
| Cash & Cash Equivalents | 470.17M |
| Total Debt | 4.74M |
| Net Cash | 465.43M |
| Net Cash Per Share | $4.89 |
| Equity (Book Value) | 459.22M |
| Book Value Per Share | 4.84 |
| Working Capital | 451.62M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$109.03 million and capital expenditures -$1.31 million, giving a free cash flow of -$110.34 million.
| Operating Cash Flow | -109.03M |
| Capital Expenditures | -1.31M |
| Free Cash Flow | -110.34M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |